Title: The Evidence Supporting Ranibizumab in the Treatment of Neovascular Age-related Macular Degeneration
Abstract:The efficacy and safety of ranibizumab in neovascular age-related macular degeneration (AMD) or wet AMD has been demonstrated in the large phase III ANCHOR and MARINA trials. Further studies includi...The efficacy and safety of ranibizumab in neovascular age-related macular degeneration (AMD) or wet AMD has been demonstrated in the large phase III ANCHOR and MARINA trials. Further studies including the PIER, PrONTO, EXCITE and SUSTAIN trials have also evaluated the optimal dosing regimen of ranibizumab. Various head-to-head studies have compared the anti-angiogenic treatments for wet AMD. The CATT and IVAN trials compared the safety and efficacy of ranibizumab with off-label use of bevacizumab and raised concern about an increased risk of ocular and systemic adverse events (AEs) in patients receiving bevacizumab compared with those receiving ranibizumab. Studies such as SAILOR and HORIZON have shown that ranibizumab has a good safety profile and is well tolerated for over 4 years with few serious ocular and systemic AEs.Read More